Which company developed the Ozempic and Wegovy medicines containing semaglutide?

Novo Nordisk developed Ozempic and Wegovy, medicines containing the active ingredient semaglutide.

Novo Nordisk is a Danish pharmaceutical company founded in 1923 through the merger of two insulin businesses. It has long specialized in diabetes care and later expanded into obesity treatment and other chronic diseases.

Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management in eligible patients. Both contain semaglutide, a medicine that mimics the hormone GLP-1 and helps regulate blood sugar and appetite.

A common mix-up is treating Ozempic and Wegovy as identical products. They share the same active ingredient but have different approved uses, dosing regimens, and labeling. Novo Nordisk also markets Rybelsus, an oral semaglutide medicine for type 2 diabetes.